Immix Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Immix Biopharma wird ein Gewinn- und Umsatzwachstum von 3.4% bzw. 76.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 22.8% pro Jahr wachsen soll.

Wichtige Informationen

3.4%

Wachstumsrate der Gewinne

22.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	76.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	07 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:IMMX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	N/A	N/A	N/A	1
12/31/2025	3	-20	N/A	-19	2
12/31/2024	1	-19	N/A	-17	2
9/30/2024	N/A	-22	-16	-16	N/A
6/30/2024	N/A	-19	-15	-15	N/A
3/31/2024	N/A	-18	-13	-13	N/A
12/31/2023	N/A	-15	-11	-11	N/A
9/30/2023	N/A	-14	-13	-13	N/A
6/30/2023	N/A	-11	-11	-11	N/A
3/31/2023	N/A	-9	-8	-8	N/A
12/31/2022	N/A	-8	-7	-7	N/A
9/30/2022	N/A	-27	-5	-5	N/A
6/30/2022	N/A	-26	-3	-3	N/A
3/31/2022	N/A	-25	-3	-3	N/A
12/31/2021	N/A	-24	-2	-2	N/A
9/30/2021	N/A	-2	0	0	N/A
6/30/2021	N/A	-2	0	0	N/A
3/31/2021	N/A	-2	0	0	N/A
12/31/2020	N/A	-1	0	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IMMX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IMMX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IMMX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IMMXDie Einnahmen des Unternehmens (76.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: IMMXDie Einnahmen des Unternehmens (76.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IMMX in 3 Jahren voraussichtlich hoch sein wird

Immix Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Deliver On Growth Plans?

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Raymond Comenzo Joins Scientific Advisory Board of Nexcella Scientific Advisory

Immix Biopharma, Inc. Announces the Addition of Three Additional Clinical Trial Sites for Its U.S. Relapsed/Refractory Al Amyloidosis Clinical Trial NEXICART-2

Independent Director recently bought US$52k worth of stock

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma, Inc. Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Insufficient new directors

New major risk - Revenue and earnings growth

Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation

Immix Biopharma, Inc., Annual General Meeting, Jun 11, 2024

Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial

New major risk - Shareholder dilution

Immix Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $14.999999 million.

New minor risk - Market cap size

Director recently bought US$267k worth of stock

Immix Biopharma, Inc. Announces New Clinical Data from Its Phase 1b/2a NEXICART-1

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

New major risk - Financial position

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Director recently bought US$200k worth of stock

Immix Biopharma, Inc Announces U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Immix Biopharma, Inc. Appoints Yekaterina Chudnovsky as Member of the Board

Immix Biopharma, Inc. Reports 2Nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1B/2A Imx-110 Imx-110 Clinical Trial

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer

Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX 110 in Advanced Solid Tumors

Immix Biopharma Announces Patient Dosing in Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Releases and Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

High number of new directors

Immix Biopharma, Inc. Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial

Immixbio Approves 4 Additional Clinical Trial Sites for Imx-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans

Immix Biopharma, Inc. Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

Immix Biopharma, Inc. Announces Positive Interim Study Data Showing That After One Cycle of Treatment, Immixbio's Lead Candidate IMX-110 Produces 75% Survival Vs. 0% Survival for Trabectedin

We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely

High number of new and inexperienced directors

Immix Biopharma, Inc., Annual General Meeting, Jun 08, 2022

Immix Biopharma, Inc. Initiates Good Manufacturing Practice Manufacturing of IMX-120

Immix Biopharma, Inc. Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles

Immix Biopharma, Inc IMX-110 Produces 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

U.S. Food and Drug Administration Approves Immix Biopharma, Inc. Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

High number of new and inexperienced directors

Immix Biopharma, Inc. has completed an IPO in the amount of $21 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken